Professional Marketing briefs: March 2013

Geno Germano
Geno Germano

Although the FDA has input on drug names, Reuters dug into what's behind brand names starting with Xs and Zs and found it's not necessarily a trademark issue. Reuters found that X and Z are memorable and that starting a drug's name with one of these letters generally means the drug will be marketed to HCPs. Reuters added the jumble may hint at what the drug does. Example: Pfizer's drug Xeljanz works on Janus Kinase molecules.

The latest Pfizer earnings call provided insight into Pfizer's marketing push for its RA drug Xeljanz. Oncology and specialty president Geno Germano confirmed the company gave 30-day supplies to a select group of rheumatologists and reception has been positive. Germano acknowledged consumer awareness isn't high, but said a DTC campaign will roll out in the middle of this year.

A PhRMA report suggests the industry is looking at a robust pipeline. Among the trade group's findings: more than 5,000 new medications are being studied and 70% are “potential first-in-class medicines.” The interest group noted that rare diseases are garnering attention, with about 140 potential medicines being researched in the past decade.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.